AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00613223
Drug: Vandetanib and Etoposide
RxNorm normalized name: Vandetanib
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 \& 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
Trial: NCT03142828
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healing abutment with Clorhexidine
Trial: NCT04047771
Drug: SCB-313
RxNorm normalized name: SCB-2019
DrugBank: SCB-2019 (DB15805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle
Trial: NCT04239950
Drug: Ethyl Icosapentate
RxNorm normalized name: Ethyl icosapentate
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ethyl Icosapentate
Trial: NCT00045097
Drug: ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03823768
Drug: Envarsus
RxNorm normalized name: Envarsus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this group will take Envarsus daily for 6 months of treatment (goal 24 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
Trial: NCT03823768
Drug: Tacrolimus Immediate release
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this group will take Tacrolimus immediate release for 6 months of treatment (goal 12 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
Trial: NCT02084355
Drug: oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01949610
Drug: 14C-JNJ26489112
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1.
Trial: NCT02084355
Drug: oral hydromorphone
RxNorm normalized name: hydromorphone Oral Solution
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02084355
Drug: fentanyl patch
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02694588
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
Trial: NCT02694588
Drug: Vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody
Trial: NCT00700947
Drug: Beta-blocker therapy (TOPROL-XL® )
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.
Trial: NCT02324309
Drug: Humulin R U-500
RxNorm normalized name: Humulin R U-500 500unit/mL Solution for Injection
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01787500
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01787500
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02908906
Drug: JNJ-63723283
RxNorm normalized name: JNJ-63723283
DrugBank: Cetrelimab (DB15421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-63723283 will be administered by IV infusion or SC injection or infusion.
Trial: NCT01858064
Drug: OROS-MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
Trial: NCT03609216
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03609216
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00093132
Drug: Satraplatin
RxNorm normalized name: Satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
Trial: NCT00224692
Drug: Low dose ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04962438
Drug: Anti-VEGF
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway
Trial: NCT00004916
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004916
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00004916
Drug: teniposide
RxNorm normalized name: Teniposide
DrugBank: Teniposide (DB00444)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00317759
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03088644
Drug: JNJ-54175446
RxNorm normalized name: JNJ-54175446
DrugBank: JNJ-54175446 (DB15358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-54175446 up to 600 mg suspension for oral dose administration.
Trial: NCT03088644
Drug: 18F-JNJ-64413739
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-JNJ-64413739 fluid for injection administered intravenously.
Trial: NCT01575041
Drug: Potassium
RxNorm normalized name: Potassium
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
Trial: NCT00068003
Drug: Anti-CD19 CAR PBL
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04067011
Drug: Ciprofloxacin 500Mg Tablet
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.
Trial: NCT03069378
Drug: Talimogene Laherparepvec (T-VEC)
RxNorm normalized name: T-Vec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .
Trial: NCT03069378
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.
Trial: NCT01489228
Drug: E1224
RxNorm normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg tablets
Trial: NCT01489228
Drug: Benznidazole
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg tablets
Trial: NCT01254578
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally
Trial: NCT02270801
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
Trial: NCT04488081
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
Trial: NCT04488081
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
Trial: NCT04488081
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
Trial: NCT01093326
Drug: Ponesimod 10 mg
RxNorm normalized name: ponesimod 10 MG
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ponesimod 10 mg oral use
Trial: NCT01093326
Drug: Ponesimod 20 mg
RxNorm normalized name: ponesimod 20 MG
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ponesimod 20 mg oral use
Trial: NCT01093326
Drug: Ponesimod 40 mg
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ponesimod 40 mg oral use
Trial: NCT04291261
Drug: Uvadex
RxNorm normalized name: Uvadex
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal photopheresis (ECP) with Uvadex is scheduled 3x/week in weeks 1+2, 2x/week thereafter till day 28 and 1x/week till day 56
Trial: NCT04488081
Drug: Cenicriviroc
RxNorm normalized name: Cenicriviroc
DrugBank: Cenicriviroc (DB11758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
Trial: NCT04488081
Drug: Icatibant
RxNorm normalized name: Icatibant
DrugBank: Icatibant (DB06196)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
Trial: NCT04488081
Drug: Apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral, 30 mg bid × 14 days.
Trial: NCT04363853
Drug: Tocilizumab 20 MG/ML
RxNorm normalized name: tocilizumab 20 MG/ML
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.
Trial: NCT00274001
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02652377
Drug: EDP-494
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10, 100 and 200 mg capsules
Trial: NCT04488081
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.
Trial: NCT04488081
Drug: Aviptadil
RxNorm normalized name: Aviptadil
DrugBank: Aviptadil (DB06260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days
Trial: NCT04488081
Drug: Cyproheptadine
RxNorm normalized name: Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.
Trial: NCT04488081
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
Trial: NCT02267915
Drug: subcutaneous Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MabThera 1400 mg solution for subcutaneous injection
Trial: NCT01105312
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01105312
Drug: panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01595438
Drug: Ceftazidime - Avibactam ( CAZ-AVI)
RxNorm normalized name: avibactam / ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
Trial: NCT01595438
Drug: Doripenem
RxNorm normalized name: Doripenem
DrugBank: Doripenem (DB06211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
Trial: NCT01595438
Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Trial: NCT04126603
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks
Trial: NCT00930709
Drug: Botulinum toxin type A (Botox®, Allergan)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
Trial: NCT01472562
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle.
Trial: NCT03604991
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03604991
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT03202316
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03202316
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03202316
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT04372121
Drug: 75 mg linzagolix tablet
RxNorm normalized name: linzagolix
DrugBank: Linzagolix (DB17083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral administration once daily
Trial: NCT04372121
Drug: 200 mg linzagolix tablet
RxNorm normalized name: linzagolix
DrugBank: Linzagolix (DB17083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral administration once daily
Trial: NCT04372121
Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg)
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For oral administration once daily
Trial: NCT04372121
Drug: Placebo tablet to match 75 mg linzagolix tablet
RxNorm normalized name: linzagolix
DrugBank: Linzagolix (DB17083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral administration once daily
Trial: NCT04372121
Drug: Placebo tablet to match 200 mg linzagolix tablet
RxNorm normalized name: linzagolix
DrugBank: Linzagolix (DB17083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral administration once daily
Trial: NCT00801489
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00801489
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00801489
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00801489
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00801489
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00292981
Drug: C1 Esterase Inhibitor
RxNorm normalized name: C1 esterase inhibitor
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
Trial: NCT02201251
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate weight based dosing for participants 2 to \<10 years of age not to exceed 350 mg/day, as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
Trial: NCT02201251
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
Trial: NCT04166409
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04166409
Drug: Selumetinib Sulfate
RxNorm normalized name: selumetinib sulfate
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04166409
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03070327
Drug: Lenalidomide.
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
Trial: NCT02877134
Drug: JNJ-64304500
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64304500 Subcutaneously.
Trial: NCT02877134
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive ustekinumab as per the dosing regimen.
Trial: NCT04022239
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04022239
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04022239
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04022239
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04022239
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV and PO
Trial: NCT02126943
Drug: Opsumit (macitentan)
RxNorm normalized name: Opsumit
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg tablets
Trial: NCT02305654
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose 175mg/m2 as part of TIP regimen.
Trial: NCT02305654
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 900mg/m2 as part of TIP regimen.